GeneExpression Systems, Inc.

Company Profile "GeneExpression Systems has been incorporated in the Commonwealth of Massachusetts in the year of 1999 by Harvard and MIT trained scientists” GES develops, applies and markets qualitative and quantitative differential gene profiling technology for down stream study of gene expression and regulation, diagnostic, predictive toxicology and therapeutic purposes. We are a molecular biology contract research organization providing reagents and services to the researchers in academic, biotechnology and pharmaceutical industries in the emerging business segments of molecular cell biology, genomics, proteomics, and bioinformatics. GES develops and commercializes proprietary gene expression kits, services and technologies to accelerate and enhance the discovery of new markers. We are developing new tools for monitoring the “Differential Gene ProfilingTM “ (DGP) to create a new “functional genomics” platform, and to maintain proprietary databases for medically (disease) relevant genes. In addition, the company intends to perform gene discovery research in the areas of cancer (colon, lung, breast) and inflammatory bowel disease (Ulcerative colitis) using state-of-the art gene expression technology platforms. Apart from this gene discovery model GeneExpression Systems, Inc. collaborates with international companies to market compatible technology/instruments/products in the US market. Our Mission Leadership in applying basic biology techniques and informatics tools in the fields of PharmacoGenomics, ToxicoGenomics, Proteomics and Clinical Genomics to create proprietary high value solutions in Applied Medical Sciences and beyond. Our commitment is to discover gene-markers for the early diagnosis of colon cancer, lung cancer and inflammatory bowel diseases utilizing the state-of-the art gene expression technology. Our core competency is the application of differential gene profiling (DGP) strategy for disease diagnosis.